How to Explain the Contradiction of microRNA 200c Expression and Survival in Solid Tumors?: a Meta-analysis

  • Wang, Hui-Yu (Nanjing Drum Tower Hospital, Clinical Cellege of Nanjing Medical University) ;
  • Shen, Jie (The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University) ;
  • Jiang, Chun-Ping (The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University) ;
  • Liu, Bao-Rui (Nanjing Drum Tower Hospital, Clinical Cellege of Nanjing Medical University)
  • Published : 2014.04.30


MicroRNA 200c is a microRNA 200 family member that plays an important role in regulation of the epithelial-to-mesenchymal transition (EMT). The prognostic value of microRNA 200c in solid tumors remains controversial because of inconsistent data. Here, we report a meta-analysis of the association of microRNA 200c expression and survival in patients with solid tumors. Pubmed was searched up to November 2013 for studies investigating microRNA 200c expression and overall survival (OS) in solid tumors. Hazard ratios (HRs) with 95% confidence intervals (CIs) for OS were extracted from each study. Pooled HR and CIs were calculated using the Mantel-Haenszel fixed-effects models. A total of five studies evaluating colorectal cancer, gastric cancer, ovarian cancer, pancreatic cancer and endometrial cancer were included in the analysis. Data were divided into tissue microRNA 200c expression group and serum microRNA 200c expression group. The combined HRs [95%CIs] estimated for OS were 0.62 [0.42-0.91] and 2.16 [1.32-3.52] respectively. Low expression of microRNA 200c in tumor tissue and high expression of microRNA 200c in serum are associated with worse survival in solid tumors. Further study is needed to elucidate this contradiction.


  1. Yu J, Ohuchida K, Mizumoto K, et al (2010). MicroRNA, hsamiR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer, 9, 169.
  2. Wang FB, Yang XQ, Yang S, et al (2011). A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients--a meta-analysis. Asian Pac J Cancer Prev, 12, 2629-35.
  3. Williamson PR, Smith CT, Hutton JL, et al (2002). Aggregate data meta-analysis with time-to-event outcomes. Stat Med, 21, 3337-51.
  4. Xu TP, Zhu CH, Zhang J, et al (2013). MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev, 14, 7085-90.
  5. Zhang L, Riethdorf S, Wu G, et al (2012). Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res, 18, 5701-10.
  6. Rokavec M, Wu W, Luo JL, et al (2012). IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell, 45, 777-89.
  7. Parmar MK, Torri V, Stewart L, (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.<2815::AID-SIM110>3.0.CO;2-8
  8. Rahbari NN, Aigner M, Thorlund K, et al (2010). Metaanalysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology, 138, 1714-26.
  9. Rana TM (2007). Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol, 8, 23-36.
  10. Scheel C, Weinberg RA (2012). Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin Cancer Biol, 22, 396-403.
  11. Shi L, Zhang S, Wu H, et al (2013). MiR-200c Increases the Radiosensitivity of Non-Small-Cell Lung Cancer Cell Line A549 by Targeting VEGF-VEGFR2 Pathway. PLoS One, 8, e78344.
  12. Thomson JM, Newman M, Parker JS, et al (2006). Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev, 20, 2202-7.
  13. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16.
  14. Toiyama Y, Hur K, Tanaka K, et al (2013). Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer. Ann Surg, doi: 10.1097/SLA.0b013e3182a6909d.
  15. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al (2012). Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med, 10, 186.
  16. Kosaka N, Iguchi H, Yoshioka Y, et al (2010). Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem, 285, 17442-52.
  17. Hurteau GJ, Carlson JA, Spivack SD, et al (2007). Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res, 67, 7972-6.
  18. Karaayvaz M, Zhang C, Liang S, et al (2012). Prognostic significance of miR-205 in endometrial cancer. PLoS One, 7, e35158.
  19. Kopp F, Oak PS, Wagner E, et al (2012). miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One, 7, e50469.
  20. Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8.
  21. Ma XL, Xiao ZL, Liu L, et al (2012). Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev, 13, 1137-44.
  22. Marchini S, Cavalieri D, Fruscio R, et al (2011). Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol, 12, 273-85.
  23. Mocellin S, Hoon D, Ambrosi A, et al (2006). The prognostic value of circulating tumor cells in patients with melanoma:a systematic review and meta-analysis. Clin Cancer Res, 12, 4605-13.
  24. Mongroo PS, Rustgi AK (2010). The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther, 10, 219-22.
  25. Nilsen TW (2007). Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet, 23, 243-9.
  26. Chang YS, Tomaso E, McDonald DM, et al (2000). Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA, 97, 14608-13.
  27. Berezovskaya O, Schimmer AD, Glinskii AB, et al (2005). Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res, 65, 2378-86.
  28. Bonnomet A, Brysse A, Tachsidis A, et al (2010). Epithelialto-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia, 15, 261-73.
  29. Chang L, Guo F, Wang Y, et al (2013). MicroRNA-200c Regulates the Sensitivity of Chemotherapy of Gastric Cancer SGC7901/DDP Cells by Directly Targeting RhoE. Pathol Oncol Res, 20, 93-8.
  30. Cittelly DM, Dimitrova I, Howe EN, et al (2012). Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther, 11, 2556-65.
  31. Cochrane DR, Spoelstra NS, Howe EN, et al (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther, 8, 1055-66.
  32. Dykxhoorn DM (2010). MicroRNAs and metastasis: little RNAs go a long way. Cancer Res, 70, 6401-6.
  33. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet, 9, 102-14.
  34. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.

Cited by

  1. Regulatory Network of MicroRNAs, Target Genes, Transcription Factors and Host Genes in Endometrial Cancer vol.16, pp.2, 2015,
  2. MicroRNA-17 family as novel biomarkers for cancer diagnosis: a meta-analysis based on 19 articles vol.37, pp.5, 2016,
  3. Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma vol.10, pp.9, 2018,